---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000033"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:17:42.362574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates

## Summary
- IBIO-610 half-life in obese NHP measured at 33.2 days.
- Predicted human half-life up to 100 days, enabling twice-yearly dosing.
- Data to be presented at ObesityWeek 2025, Nov 4-7 in Atlanta by Cory Schwartz, Ph.D.
- IBIO-610 is a potential first-in-class Activin E antibody for fat-selective weight loss.
- Previously showed GLP-1-synergistic weight loss and prevention of weight regain in mouse models.

## SEC filing metadata
- accession: 0001420720-25-000033
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/0001420720-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/ibio-20251030x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000033
- JSON: https://secwatch.observer/filing/0001420720-25-000033.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.